Nimoli Pharmaceuticals (P) Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
- Paid Up Capital ₹ 2.60 M
- Company Age 26 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.11 Cr
About Nimoli Pharmaceuticals (P)
Nimoli Pharmaceuticals (P) Ltd. (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 August 1998 and has a history of 26 years and six months. Its registered office is in Delhi, India.
The Corporate was formerly known as Nimoli Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 2.60 M.
The company has closed loans amounting to ₹1.11 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Vimla Sharma, Vinod Sharma, and Sudesh Bansal serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232DL1998PTC361925
- Company No.
033999
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Aug 1998
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Nimoli Pharmaceuticals (P)?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vimla Sharma  | Director | 16-Aug-2005 | Current |
| Vinod Sharma | Director | 04-Aug-1998 | Current |
| Sudesh Bansal | Director | 16-Aug-2005 | Current |
Financial Performance of Nimoli Pharmaceuticals (P).
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nimoli Pharmaceuticals (P)?
Unlock access to Nimoli Pharmaceuticals (P)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹0
₹11.05 M
Charges Breakdown by Lending Institutions
- Axis Bank Limited : 0.75 Cr
- Icici Bank Limited : 0.36 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Jun 2017 | Axis Bank Limited | ₹7.50 M | Satisfied |
| 13 Jan 2011 | Icici Bank Limited | ₹3.55 M | Satisfied |
How Many Employees Work at Nimoli Pharmaceuticals (P)?
Unlock and access historical data on people associated with Nimoli Pharmaceuticals (P), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nimoli Pharmaceuticals (P), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nimoli Pharmaceuticals (P)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
